Sargramostim — Discount Pricing

Other medications in Blood Disorders

• Tranexamic Acid
• Voxelotor
• Aminocaproic Acid
• Avatrombopag
• Crizanlizumab
• Darbepoetin
• Desmopressin IV
• Eltrombopag

About Sargramostim

Sargramostim is a vital medication used to stimulate white blood cell production, crucial for patients undergoing specific cancer treatments or transplants. Understanding its role and how to access it affordably is key. TheDrugClub is dedicated to making essential medications like sargramostim accessible, offering eligible members significant savings, often reducing their out-of-pocket costs to $0.

Sargramostim, known commercially as Leukine®, is a powerful medication designed to support your body's immune system when it's most vulnerable. It's a synthetic version of a naturally occurring protein, granulocyte-macrophage colony-stimulating factor (GM-CSF), which plays a critical role in the production and maturation of white blood cells, specifically neutrophils, monocytes, and macrophages.

What Sargramostim Treats

This medication is primarily prescribed to help patients recover from treatments that suppress bone marrow function. Its main uses include:

• Myeloid reconstitution after bone marrow transplantation: Whether you've received an autologous (your own cells) or allogeneic (donor cells) bone marrow transplant, sargramostim helps speed up the recovery of your white blood cell count, reducing the risk of life-threatening infections.
• Acute Myeloid Leukemia (AML): Following chemotherapy for AML, sargramostim can help shorten the time to neutrophil recovery, aiding in the fight against infection.
• Mobilization of peripheral blood progenitor cells (PBPCs): It's used to increase the number of stem cells in the bloodstream before collection, which are then used in autologous transplantation.
• Bone marrow transplant failure or engraftment delay: In cases where the transplanted marrow doesn't start producing blood cells as expected, sargramostim can encourage recovery.

How It Works

Sargramostim works by binding to specific receptors on myeloid progenitor cells in the bone marrow. This stimulates these cells to proliferate and differentiate into various types of mature white blood cells. By increasing the number of these infection-fighting cells, sargramostim helps bolster the body's natural defenses, particularly after intensive treatments like chemotherapy or radiation that can severely deplete them.

Understanding Typical Costs

As a specialized biologic medication, sargramostim comes with a significant price tag. Without insurance, or with high deductibles and co-pays, a single course of treatment can easily run into thousands of dollars. These high costs can be a major barrier, adding immense financial stress to patients already battling serious health conditions. The financial burden often forces individuals to make difficult choices about their care.

TheDrugClub: Your $0 Co-pay Solution with Free Home Delivery

At TheDrugClub, we believe that critical medications like sargramostim should be accessible and affordable. We work tirelessly to connect eligible members with manufacturer patient assistance programs, allowing them to receive their sargramostim for a

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sargramostim is approved for (FDA label)

LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) 1.1 Acute Myeloid Leukemia Following Induction Chemotherapy LEUKINE is indicated to shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). 1.2 Autologous Peripheral Blood Progenitor Cell Mobilization and Collection LEUKINE is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis. 1.3 Autologous Peripheral Blood Progenitor Cell and Bone Marrow Transplantation LEUKINE is indicated for the acceleration of myeloid reconstitution following autologous peripheral blood progenitor cell (PBPC) or bone marrow transplantation in adult and pediatric patients 2 years of age and older with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin's lymphoma (HL). 1.4 Allogeneic Bone Marrow Transplantation LEUKINE is indicated for the acceleration of myeloid reconstitution in adult and pediatric patients 2 years of age and older undergoing allogeneic bone marrow transplantation from HLA-matched related donors. 1.5 Allogeneic or Autologous Bone Marrow Transplantation: Treatment of Delayed Neutrophil Recovery or Graft Failure LEUKINE is indicated for the treatment of adult and pediatric patients 2 years and older who have undergone allogeneic or autologous bone marrow transplantation in whom neutrophil recovery is delayed or failed. 1.6 Acute Exposure to Myelosuppressive Doses of Radiation (H-ARS) LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

Source: Read the full FDA label on DailyMed. Label effective date: December 6, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sargramostim (FDA label)

For injection: 250 mcg of sargramostim as a white lyophilized powder in a single-dose vial for reconstitution For injection (lyophilized powder): 250 mcg of sargramostim in single-dose vial for reconstitution ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: bb9a3820-f31a-4dd9-bef4-97094c01a398. SPL document ID: 4ad3993c-6c7f-4a33-8ead-a912636ff4a1. Label effective date: December 6, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sargramostim (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Infusion Related Reactions [see Warnings and Precautions ( 5.2 )] Risk of Severe Myelosuppression when LEUKINE Administered within 24 Hours of Chemotherapy or Radiotherapy [see Warnings and Precautions ( 5.3 )] Effusions and Capillary Leak Syndrome [see Warnings and Precautions ( 5.4 )] Supraventricular Arrhythmias [see Warnings and Precautions ( 5.5 )] Leukocytosis [see Warnings and Precautions ( 5.6 )] Potential Effect on Malignant Cells [see Warnings and Precautions ( 5.7 )] Immunogenicity [see Warnings and Precautions ( 5.8 )] Risk of Serious Adverse Reactions in Infants Due to Benzyl Alcohol Preservative [see Warnings and Precautions ( 5.9 )] The most common adverse reactions (incidence >30%) were ( 6.1 ): In recipients of autologous BMT: fever, nausea, diarrhea, vomiting, mucous membrane disorder, alopecia, asthenia, malaise, anorexia, rash, gastrointestinal disorder and edema.

Source: FDA prescribing information (DailyMed). Set ID: bb9a3820-f31a-4dd9-bef4-97094c01a398. SPL document ID: 4ad3993c-6c7f-4a33-8ead-a912636ff4a1. Label effective date: December 6, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sargramostim (FDA label)

Do not administer LEUKINE to patients with a history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factor such as sargramostim, yeast-derived products, or any component of the product. Anaphylactic reactions have been reported with LEUKINE [see Warnings and Precautions ( 5.1 )] . Do not administer LEUKINE to patients with a history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the product. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: bb9a3820-f31a-4dd9-bef4-97094c01a398. SPL document ID: 4ad3993c-6c7f-4a33-8ead-a912636ff4a1. Label effective date: December 6, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sargramostim (FDA label)

Hypersensitivity Reactions: Permanently discontinue LEUKINE in patients with serious allergic reactions. ( 5.1 ) Infusion Related Reactions: Manage using infusion rate reductions or discontinuations. ( 5.2 ) Effusions and Capillary Leak Syndrome: Manage with dose-reduction, discontinuation, or diuretics. Monitor body weight and hydration status during therapy. ( 5.4 ) Supraventricular Arrhythmias: Risk may be increased in patients with history of cardiac arrhythmias. Manage medically and discontinue LEUKINE. ( 5.5 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with LEUKINE. Parenteral administration of LEUKINE should be attended by appropriate precautions in case an allergic or untoward reaction occurs. If any serious allergic or anaphylactic reaction occurs, immediately discontinue LEUKINE therapy and institute medical management. Discontinue LEUKINE permanently for patients with serious allergic reactions. 5.2 Infusion Related Reactions LEUKINE can cause infusion-related reactions.

Source: FDA prescribing information (DailyMed). Set ID: bb9a3820-f31a-4dd9-bef4-97094c01a398. SPL document ID: 4ad3993c-6c7f-4a33-8ead-a912636ff4a1. Label effective date: December 6, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sargramostim (FDA label)

Use with caution in patients receiving drugs that may potentiate LEUKINE's myeloproliferative effects, such as lithium and corticosteroids. ( 7.1 ) 7.1 Concomitant Use with Products that Induce Myeloproliferation Avoid the concomitant use of LEUKINE and products that induce myeloproliferation (such as lithium and corticosteroids). Such products may increase the myeloproliferative effects of LEUKINE. Monitor patients receiving both LEUKINE and products that induce myeloproliferation frequently for clinical and laboratory signs of excess myeloproliferative effects.

Source: FDA prescribing information (DailyMed). Set ID: bb9a3820-f31a-4dd9-bef4-97094c01a398. SPL document ID: 4ad3993c-6c7f-4a33-8ead-a912636ff4a1. Label effective date: December 6, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.